BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approval of BCMA-targeted chimeric antigen receptor (CAR)-T cell therapies in RRMM. With now two a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, James F., Dhakal, Binod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385907/
https://www.ncbi.nlm.nih.gov/pubmed/37507805
http://dx.doi.org/10.1186/s13045-023-01479-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385907/
https://www.ncbi.nlm.nih.gov/pubmed/37507805
http://dx.doi.org/10.1186/s13045-023-01479-5

Ejemplares similares